NCT05998525View on ClinicalTrials.gov

Dapagliflozin Effects on Coronary Calcium and Epicardial Fat Assessed by Cardiotomography

PHASE3CompletedINTERVENTIONAL
Enrollment

54

Participants

Timeline

Start Date

June 21, 2021

Primary Completion Date

December 30, 2022

Study Completion Date

June 1, 2023

Conditions
Diabete Type 2Unstable AnginaMyocardial InfarctionDiabetes Mellitus, Type 2
Interventions
DRUG

Dapagliflozin 10Mg Tab

patients who meet the inclusion criteria and after catheterization will be randomized to receive Dapagliflozin 10 mg every 24 hours and upon dischargetreatment will continue for 12 months

DRUG

Placebo

patients who meet the inclusion criteria and after catheterization will be randomized to receive a placebo pill 24 hours and upon discharge treatment will continue for 12 months

Trial Locations (1)

37260,

Unidad Medica de Alta Especialidad No. 1, Bajío, León

All Listed Sponsors
lead

Hilda Elizabeth Macías Cervantes

OTHER_GOV